Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasm, Residual × Sorafenib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Hepatocellular 8 Liver Neoplasms 3 Leukemia, Myeloid, Acute 2 Neoplasm, Residual 1 Leukemia, Monocytic, Acute 1

Interventions

venetoclax 1 sugemalimab 1 Tyrosine Kinase Inhibitors 1 Sorafenib 1 Methotrexate 1 Fish Oils 1 Docosahexaenoic Acids 1 Cytarabine 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡